Clinical trials: Neuroectodermal Tumors, Primitive
Sarcoma, Osteosarcoma
A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors
Background GD2 is a well-characterized tumor antigen in neuroblastoma, which is also expressed on osteosarcomas and some other sarcomas.
- Conditions
- Sarcoma, Osteosarcoma, Neuroblastoma, Melanoma
- Trial name
- NCT02107963
- Testing
- Anti-GD2-CAR engineered T cells, AP1903, Cyclophosphamide
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Neuroblastoma
High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma
This is a pilot study to determine whether doses of 15 mCi/kg and 18 mCi/kg of 131I-MIBG are tolerable when given with irinotecan/vincristine on a one week schedule to children and young adults with high-risk refractory/relapsed…
- Trial name
- NCT01313936
- Testing
- Metaiodobenzylguanidine (MIBG)
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of California, San Francisco
Brain Tumor, Medulloblastoma
Quantitative Assessment of Radiation-induced Neuroinflammation - A Proof of Principle Study
QARIN 1 is a study of [18F]DPA-714 Translocation Protein (TSPO) Positron Emission Tomography (PET) for longitudinal, quantitative assessment of brain neuroinflammation following whole brain radiation therapy.
- Trial name
- NCT05128903
- Testing
- [18F]DPA714
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- St. Jude Children's Research Hospital
Midgut Neuroendocrine Tumours, Pancreatic Neuroendocrine Tumours
Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study
Two parallel phase II randomized open label trials of Lutetium-177 Octreotate (177Lu-Octreotate) peptide receptor radionuclide therapy (PRRT) and capecitabine (CAP)/temozolomide (TEM) chemotherapy (chemo): (i) versus CAPTEM alone…
- Trial name
- CONTROL NETS (NCT02358356)
- Testing
- octreotate, Capecitabine, Temozolomide
- Where
- 4 sites in Australia
- Volunteers
- 75 people
- Sponsor
- Australasian Gastro-Intestinal Trials Group
Lymphoma, Neuroblastoma
Whole-Body MRI and Conventional Imaging in Detecting Distant Metastases in Young Patients With Solid Tumors or Lymphoma
RATIONALE: New imaging procedures, such as whole-body MRI, may improve the ability to detect metastatic cancer and determine the extent of disease.
- Conditions
- Lymphoma, Neuroblastoma, Sarcoma
- Trial name
- NCT00072488
- Testing
- computed tomography, magnetic resonance imaging, positron emission tomography
- Where
- 21 sites in United States, Canada
- Volunteers
- 226 people
- Sponsor
- American College of Radiology Imaging Network
Well-differentiated Non-functional NET of Thoracic Origin, Well-differentiated Non-functional NET of Gastrointestinal Origin
Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
This study aimed to investigate the efficacy and safety of PDR001 in patients with advanced or metastatic, well-differentiated, non-functional neuroendocrine tumors of pancreatic, gastrointestinal (GI), or thoracic origin or…
- Conditions
- Well-differentiated Non-functional NET of Thoracic Origin, Well-differentiated Non-functional NET of Gastrointestinal Origin, Well-differentiated Non-functional NET of Pancreatic Origin, Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma
- Trial name
- NCT02955069
- Testing
- PDR001
- Where
- 35 sites in United States, Australia and 10 more
- Volunteers
- 116 people
- Sponsor
- Novartis Pharmaceuticals
Brain and Central Nervous System Tumors
Surgery Plus Radiation Therapy With or Without Chemotherapy in Treating Children With Primitive Neuroectodermal Tumors of the CNS
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003859
- Testing
- carboplatin, cyclophosphamide, etoposide
- Where
- United Kingdom
- Volunteers
- 230 people
- Sponsor
- Societe Internationale d'Oncologie Pediatrique
Refractory Cancer, CNS Tumors
A Study of Avutometinib for People With Solid Tumor Cancers
The purpose of this study is to find out whether avutometinib is a safe treatment for advanced or recurrent solid tumor cancers in children and young adults.
- Conditions
- Refractory Cancer, CNS Tumors, CNS Tumor, Adult, CNS Tumor, Childhood
- Trial name
- NCT06104488
- Testing
- Avutometinib
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Central Nervous System Neoplasms, Brain Tumor
B7-H3.CD28Z.CART in CNS Neoplasms
The purpose of this research study is to test the safety and effectiveness of a cell therapy at different doses for children and young adults with recurrent or progressive brain tumors.
- Conditions
- Central Nervous System Neoplasms, Brain Tumor, Brain Tumor, Recurrent, Brain Tumor, Pediatric
- Trial name
- NCT07390539
- Testing
- B7-H3.CD28Z.CART, Fludarabine, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- Robbie Majzner
Medulloblastoma
CSIMEMPHIS: Long-term Follow-up of Medulloblastoma Survivors That Received Craniospinal Irradiation
The study is being done to learn more about the long-term health and well-being of participants treated for medulloblastoma. The study is to decide which evaluations focusing on therapy-related lasting effects (or toxicities)…
- Trial name
- NCT07085325
- Where
- United States
- Volunteers
- 184 people
- Sponsor
- St. Jude Children's Research Hospital
Neuroblastoma, Relapsed Neuroblastoma
67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma
The aim of this study is to evaluate the safety and efficacy of 67Cu-SARTATE in pediatric patients with high-risk neuroblastoma.
- Conditions
- Neuroblastoma, Relapsed Neuroblastoma, Refractory Neuroblastoma
- Trial name
- NCT04023331
- Testing
- 67Cu-SARTATE, 64Cu-SARTATE
- Where
- 8 sites in United States
- Volunteers
- 21 people
- Sponsor
- Clarity Pharmaceuticals Ltd
Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma
Pharmacokinetics of Ch14.18 in Younger Patients With High-Risk Neuroblastoma
This research trial is studying how Ch14.18 acts in the body of younger patients with high-risk neuroblastoma. Studying samples of blood from patients with cancer receiving Ch14.18 may help doctors learn more about how this drug…
- Conditions
- Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Neurotoxicity Syndrome, Pain
- Trial name
- NCT01418495
- Testing
- Cytology Specimen Collection Procedure, Pharmacological Study
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors, Kidney Cancer
Early Enteral Tube Feedings in Children Receiving Chemo for AML/MDS & High Risk Solid Tumors
RATIONALE: Tubefeeding may help maintain good nutrition and lessen weight loss in younger patients receiving chemotherapy for cancer.
- Conditions
- Brain and Central Nervous System Tumors, Kidney Cancer, Leukemia, Liver Cancer
- Trial name
- NCT00624962
- Testing
- nutritional intervention, therapeutic nutritional supplementation
- Sponsor
- Vanderbilt University
Brain and Central Nervous System Tumors, Metastatic Cancer
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver radioactive tumor-killing substances to them without harming normal cells. This may be effective treatment for primary or metastatic brain tumors.
- Conditions
- Brain and Central Nervous System Tumors, Metastatic Cancer, Neuroblastoma
- Trial name
- NCT00003461
- Testing
- surgical procedure, astatine At 211 monoclonal antibody 81C6
- Where
- United States
- Sponsor
- Duke University
Neuroblastoma, Pheochromocytoma
Expanded Access Protocol Using 131I-MIBG
Protocol JDI2007-01 is an Expanded Access Protocol with therapeutic 131I-MIBG for patients with neuroblastoma or pheochromocytoma / paraganglioma, who otherwise do not qualify for available treatments, or where approved treatment…
- Conditions
- Neuroblastoma, Pheochromocytoma, Paraganglioma
- Trial name
- NCT01590680
- Testing
- I-131 MIBG
- Where
- 19 sites in United States
- Sponsor
- Jubilant DraxImage Inc.
Sarcoma, Wilm's Tumor
Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer
This study will examine the safety and efficacy of ipilimumab-an experimental cancer treatment drug used to boost immune response-in children, adolescents, and young adults.
- Conditions
- Sarcoma, Wilm's Tumor, Lymphoma, Neuroblastoma
- Trial name
- NCT01445379
- Testing
- Ipilimumab
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- National Cancer Institute (NCI)
Neuroblastoma, Pheochromocytoma
18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System
This is a prospective Phase 2 study being performed to document the relationship between 18F-mIBG positron emission tomography (PET) findings in subjects, and expression of the norepinephrine transporter.
- Conditions
- Neuroblastoma, Pheochromocytoma, Paraganglioma
- Trial name
- NCT06233903
- Testing
- 18F-mFBG
- Where
- United States
- Sponsor
- Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
Cancer
Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections
RATIONALE: White blood cells that have been treated in the laboratory may kill cells that are infected with cytomegalovirus. PURPOSE: This phase I trial is studying how well cytotoxic T cells work in treating patients who have…
- Trial name
- NCT00769613
- Testing
- cytomegalovirus IE-1-specific cytotoxic T lymphocytes, cytomegalovirus pp65-specific cytotoxic T lymphocytes, therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Milton S. Hershey Medical Center
Neuroblastoma, Bone Marrow, Sympathetic Nervous System
Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma
Funding Source - FDA OOPD FDR004128 The goal of this study is to see if it is safe and feasible to give chemotherapy, natural killer (NK) cells, and an antibody called 3F8.
- Trial name
- NCT00877110
- Testing
- cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Sarcoma, Neuroblastoma
A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors
Background: Pazopanib, a drug that inhibits the growth of new blood vessels in tumors, was recently approved by the Food and Drug Administration to treat advanced kidney cancer in adults.
- Conditions
- Sarcoma, Neuroblastoma, Wilms Tumor, Osteosarcoma
- Trial name
- NCT01130623
- Testing
- Pazopanib (GW786034)
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.